lacosamide / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

44 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lacosamide / Generic mfg.
NCT00238524: A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy

Completed
3
357
Europe
SPM 927
UCB Pharma
Diabetic Neuropathy
01/05
01/05
NCT00135109: Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy

Completed
3
654
US
SPM 927
UCB Pharma
Diabetic Neuropathies
12/05
12/05
NCT00220415 / 2004-000290-58: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Completed
3
Europe
SPM 927
UCB Pharma
Partial Seizures With or Without Secondary Generalization
01/06
01/06
NCT00136019: SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Completed
3
400
US
SPM 927
UCB Pharma
Epilepsy
08/06
08/06
NCT00350103 / 2005-005788-27: A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy

Completed
3
551
Europe
SPM 929, Lacosamide, Placebo
UCB Pharma, SCHWARZ BIOSCIENCES GmbH - Part of UCB Group
Painful Diabetic Neuropathy
06/07
06/07
NCT00220337 / 2004-000960-28: A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy

Completed
3
371
Europe
Lacosamide, SPM 927
UCB Pharma, SCHWARZ BIOSCIENCES GmbH - Part of UCB Group
Painful Diabetic Neuropathy
10/07
10/07
NCT00655551 / 2014-004378-40: Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

Completed
3
100
US
lacosamide, Vimpat
UCB BIOSCIENCES, Inc.
Partial Epilepsies, Partial Onset Seizures
09/09
09/09
NCT00522275 / 2014-004398-18: Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Completed
3
308
US
lacosamide
UCB BIOSCIENCES, Inc.
Partial Epilepsies
10/09
10/09
NCT00655486 / 2014-004384-21: Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

Completed
3
97
US
lacosamide, Vimpat
UCB BIOSCIENCES, Inc.
Partial Epilepsies, Partial Onset Seizures
06/10
06/10
NCT00515619 / 2004-000152-16: Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures

Completed
3
376
Europe, RoW
Lacosamide, SPM 927, LCM
UCB Pharma
Epilepsy
08/10
08/10
NCT00546351 / 2004-000551-42: Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.

Completed
3
621
Europe, RoW
Lacosamide, Vimpat
UCB Pharma
Painful Diabetic Neuropathy
01/11
01/11
NCT01981447: IV Lacosamide: The Safety of Intravenous Lacosamide

Completed
3
40
US
IV Lacosamide, Vimpat
Le Bonheur Children's Hospital
Epilepsy
08/12
08/12
ALEX-MT, NCT00520741 / 2007-005439-27: Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Completed
3
426
Canada, US, Europe, RoW
Lacosamide, Vimpat
UCB BIOSCIENCES, Inc.
Epilepsy
12/12
12/12
VICTOR, NCT01375374 / 2010-022534-84: Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide

Terminated
3
11
Europe
Lacosamide, Vimpat, Levetiracetam, Keppra
UCB Pharma
Epilepsy, Partial
03/13
03/13
VERVE, NCT01484977 / 2011-002461-37: eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

Completed
3
120
US, Europe, RoW
Lacosamide, VIMPAT®, SPM927, Harkoseride
UCB Pharma
Epilepsy
12/13
12/13
NCT01345058: Add on Lacosamide Versus High Dose Monotherapy

Completed
3
56
US
lacosamide, Vimpat, levetiracetam
Brigham and Women's Hospital
Epilepsy
02/14
10/14
NCT01710657 / 2014-003622-41: A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures

Completed
3
548
Japan, RoW
Lacosamide 50 mg, Vimpat, Lacosamide 100 mg, Placebo
UCB Pharma SA, UCB Japan Co. Ltd.
Epilepsy, Partial Onset Seizures
07/14
08/14
NCT02192814: Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures

Completed
3
9
Japan
Lacosamide (200 mg/20 mL), Vimpat
UCB Japan Co. Ltd., Parexel
Epilepsy, Partial-onset Seizures
10/14
12/14
NCT00530855 / 2007-005440-25: Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

Completed
3
322
Canada, US, Europe, RoW
Lacosamide, Vimpat
UCB Pharma
Epilepsy
12/14
12/14
SP0993, NCT01243177 / 2010-019765-28: Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

Completed
3
888
Europe, Canada, Japan, US, RoW
Lacosamide, Vimpat®, Carbamazepine-Controlled Release, Tegretol® Retard Tablets 200 mg
UCB BIOSCIENCES GmbH, Eden Sarl
Epilepsy, Monotherapy
07/15
08/15
NCT02726867: Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus

Withdrawn
3
0
US
levetiracetam, Keppra, lacosamide, Vimpat, Ketamine, Ketalar, Phenobarbital, Phenobarb
Mid-Atlantic Epilepsy and Sleep Center, LLC
Epilepsy, Status Epilepticus
11/16
11/16
NCT01465997 / 2010-021238-74: Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

Completed
3
551
Canada, Japan, US, Europe, RoW
Lacosamide, VIMPAT film-coated tablets, Carbamazepine-Controlled Release (CBZ-CR), Tegretol® Retard Tablets 200 mg
UCB BIOSCIENCES GmbH, Eden Sarl
Epilepsy, Monotherapy
01/17
01/17
NCT01921205 / 2012-004996-38: Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures

Completed
3
404
US, Europe, RoW
Lacosamide, Vimpat(R), Placebo
UCB Pharma
Epilepsy
01/17
01/17
2015-001769-14: Antiepileptic drug for the management of acute pain posthoracotomy Antiepiléptico para el manejo del dolor agudo postoracotomía

Ongoing
3
66
Europe
LACOSAMIDE, Solution for infusion in administration system, VIMPAT 10 mg/ml solution for infusion
Javier E. Morales Sarabia, Consorcio Hospital General Universitario de Valencia
Acute postoperative pain Dolor agudo postoperatorio, postoperative pain door tras intervención quirúrgica, Diseases [C] - Symptoms and general pathology [C23]
 
 
NCT01911975 / 2013-001511-70: Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy

Completed
3
25
Europe
Lacosamide, Vimpat, Placebo, Microcrystalline cellulose
Academisch Ziekenhuis Maastricht
Small Fiber Neuropathy
05/17
05/17
NCT02374567: Pharmacovigilance in Gerontopsychiatric Patients

Terminated
3
407
Europe
Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine, Valproic Acid, Lamotrigine, Topiramate, Gabapentin, Levetiracetam, Pregabalin, Lacosamide, Clonazepam, Biperiden, Levomepromazine, Fluphenazine, Perphenazine, Perazine, Thioridazine, Haloperidol, Melperone, Pipamperone, Bromperidol, Benperidol, Sertindole, Ziprasidone, Flupentixol, Chlorprothixene, Zuclopenthixol, Fluspirilene, Pimozide, Clozapine, Olanzapine, Quetiapine, Sulpiride, Tiapride, Amisulpride, Prothipendyl, Risperidone, Aripiprazole, Paliperidone, Diazepam, Oxazepam, Lorazepam, Bromazepam, Clobazam, Alprazolam, Hydroxyzine, Buspirone, Chloral Hydrate, Flurazepam, Nitrazepam, Triazolam, Lormetazepam, Temazepam, Midazolam, Brotizolam, Zopiclone, Zolpidem, Zaleplon, Melatonin, Clomethiazole, Diphenhydramine, Promethazine, Imipramine, Clomipramine, Opipramol, Trimipramine, Amitriptyline, Nortriptyline, Doxepin, Maprotiline, Amitriptyline oxide, Fluoxetine, Citalopram, Paroxetine, Sertraline, Fluvoxamine, Escitalopram, Tranylcypromine, Moclobemide, Mianserin, Trazodone, Mirtazapine, Bupropion, Venlafaxine, Reboxetine, Duloxetine, Agomelatine, Pyritinol, Piracetam, Donepezil, Rivastigmine, Galantamine, Memantine, Nicergoline, Acamprosate, Lithium
Hannover Medical School
Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
06/17
06/17
NCT02124564: A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

Completed
3
19
Japan
Lacosamide, Vimpat
UCB Japan Co. Ltd.
Epilepsy, Partial-onset Seizures
11/17
11/17
VALOR, NCT02408523 / 2011-003100-21: A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Completed
3
242
Europe, Japan, US, RoW
Lacosamide Tablet, Vimpat, Lasosamide Oral Solution, Placebo Tablet, Placebo Oral Solution
UCB BIOSCIENCES, Inc., Pharmaceutical Research Associates
Epilepsy
04/19
06/19
NCT01832038 / 2019-004756-11: Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

Completed
3
473
Japan, RoW
Lacosamide, Vimpat
UCB Pharma SA, UCB Japan Co. Ltd.
Epilepsy, Partial-onset Seizures
07/19
07/19
NCT02582866 / 2015-001549-96: A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994

Completed
3
106
Europe, Japan, RoW
Lacosamide, Vimpat, SPM927, LCM
UCB Biopharma S.P.R.L., Parexel
Epilepsy
01/20
01/20
NCT02477839 / 2013-000717-20: Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures

Completed
3
255
Europe, US, RoW
Lacosamide, Vimpat, UCB Code: SPM 927, Abbreviated name: LCM, Placebo, PBO
UCB BIOSCIENCES, Inc.
Epilepsy With Partial-onset Seizures
05/20
05/20
2021-003392-34: Aggressive or less aggressive treatment of persistent epileptic seizures

Ongoing
3
140
Europe
Briviracetam, e.g. Keppra, e.g. Topimax, e.g. orfiril, Vimpat, n.a. many producers, different producers, Concentrate and solvent for solution for infusion, Infusion, Tablet, Briviract, Levetiracetam, Fosfenytoin, Topriamate, Orfiril/valproic acid, Vimpat, Propofol, Midazolam
Odense Universitetshospital, In-house funding Odense University Hospital
Verfied non convulsive status epilepticus refractory to standard treatment with benzodiazepines and at least one first line drug, Persistent epileptic seizures that do not respond to standard treatment, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT01964560 / 2012-005012-26: A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Completed
3
540
Europe, US, RoW
Lacosamide, VIMPAT
UCB BIOSCIENCES, Inc., UCB Biopharma SRL
Epilepsy
04/22
04/22
EDCLAS, NCT05626140: COMPARISON OF EFFICACY OF DIFFERENT DRUG COMBINATIONS IN ACUTE SCIATICA

Completed
3
120
RoW
Lacosamide 50 MG Oral Tablet [Vimpat], Lacolap 50 mg, Vimpat 50 mg, Lalap 50 mg, Codeine Phosphate, Diclofenac Sodium, Artifen 50 mg, Dicloran 50 mg
Pakistan Institute of Medical Sciences, Riphah International University
Sciatica Acute, Sciatica
05/22
07/22
VALUE, NCT02408549 / 2012-001770-29: Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

Completed
3
239
Europe, Japan, US, RoW
Lacosamide Tablet, Vimpat, LCM, Lacosamide Oral Solution
UCB BIOSCIENCES, Inc.
Epilepsy
03/23
03/23
NCT05851781: Lacosamide Versus Propranolol in Migraine

Completed
3
600
RoW
Lacosamide tablet, Propranolol
Kafrelsheikh University
Migraine Disorders
07/23
08/23
NCT05632133: The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients

Completed
3
200
RoW
Lacosamide 50 MG Oral Tablet, Ibuprofen 400 mg, control
Kafrelsheikh University
Effect of Drug, Migraine Disorders
08/23
08/23
NCT06243692: Lacosamide Versus Topiramate in Migraine

Recruiting
3
600
RoW
Lacosamide 50 MG, group A, Topiramate 50Mg Tab, group B
Kafrelsheikh University
Migraine Disorders
02/25
02/25
NCT05291455: Lacosamide in Neonatal Status Epilepticus

Recruiting
3
60
RoW
Lacosamide, lacosa, Phenobarbital, phenobarbitone
Sherief Abd-Elsalam
Epilepsy
03/24
04/24
NCT04627285 / 2020-001478-30: A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment

Active, not recruiting
3
48
Europe, RoW
Lacosamide
UCB Biopharma SRL
Epilepsy
07/25
07/25
NCT00235469: A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

Completed
2/3
496
US
SPM 927
UCB Pharma
Diabetic Neuropathy
06/05
06/05
NCT00151879 / 2004-002322-22: Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

Completed
2/3
160
US
SPM 927
UCB Pharma
Epilepsies, Partial
05/06
05/06
NCT00235443: A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy

Completed
2/3
451
US
lacosamide, SPM927
UCB Pharma
Diabetic Neuropathy
07/08
07/08
ASPIRE, NCT02710890 / 2014-003294-42: Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.

Completed
2/3
103
Europe, US, RoW
Lacosamide, Vimpat
UCB BIOSCIENCES, Inc.
Epilepsy
06/19
06/19

Download Options